Background: The factors related to ascending aorta dilation (AAD) in patients with bicuspid aortic valve (BAV) are not completely understood. In addition, the role of cholesterol metabolism in AAD has not been studied. Methods: We analyzed the relationship between different lipid parameters and the ascending aorta diameter/presence of aortic dilatation in 91 consecutive patients with BAV. Results: We observed a positive linear correlation between the total cholesterol, low-density lipoprotein (LDL) cholesterol and apolipoprotein B (ApoB) levels and the ascending aorta diameter. The
Introduction
Bicuspid aortic valve (BAV) is the most common congenital cardiac malformation. BAV is commonly associated with the development of clinically relevant complications, such as aortic valve dysfunction, infectious endocarditis, ascending aorta dilatation (AAD) and aortic dissection. 1 AAD is especially problematic because it is involved in the mechanism of aortic regurgitation in BAV, 2 and it increases aortic stiffness 3 and the risk of aortic dissection, 4 which frequently leads to the need for prophylactic aortic surgery. 5 The mechanisms that underlie aortic dilatation have been a matter of debate for years; the proposed causes include anomalous flow in the ascending aorta generated by the anomalous dynamics of BAV 6, 7 and genetic causes responsible for the anomalous structure of the aortic media. 8, 9 However, to date, the physiopathology of AAD in BAV patients has not been completely explained, which suggests that other mechanisms are implicated.
Serum lipoproteins have been related to abdominal aortic dilatation [10] [11] [12] [13] . Thus, the aim of this study was to analyze the potential role of lipid metabolism-related parameters on the ascending aorta diameter and aortic dilation in patients with BAV.
Patients and methods
We studied 91 consecutive patients diagnosed with BAV who were prospectively introduced in our database. All patients underwent an echocardiogram upon inclusion. BAV was diagnosed when two aortic leaflets were clearly visualized with or without raphe on the parasternal short-axis view of a transthoracic echocardiogram.
14 When this procedure was considered insufficient for a definitive diagnosis of BAV, a transesophageal echocardiogram 14 or cardiac magnetic resonance imaging 15 was performed according to the clinical criteria. All explorations were performed or reviewed upon inclusion by the same observer (J.M.A.). Valve morphotype (i.e. the pattern of cusp fusion) was categorized as typical (fusion between right and left coronary cusps) or atypical (other morphotypes, mainly fusion between right and non coronary cusps). 16 Once BAV was diagnosed, a blood sample was obtained and stored in our BAV biobank. Dilatation of the aortic root or ascending aorta was diagnosed when the corresponding diameter was !40 mm. The aortic morphology was categorized in three phenotypes depending on the aortic dilatation pattern: non-dilation phenotype, ascending phenotype (dilatation on the ascending aorta with normal or less dilatation on the aortic root) and root phenotype (dilatation in the aortic root with normal or less dilatation on the ascending aorta). 16 This study was approved by the Institutional Review Board (the Clinical Ethics Committee) of our institution. Written informed consent was obtained from all patients who participated in this study.
Biochemical parameters, including the levels of cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), apolipoproteins AI and B100, lipoprotein (Lp) (a) and C-reactive protein, were measured using colorimetric, enzymatic and immunoturbidimetric assays (Spinreact, SA, Girona, Spain; HORIBA ABX, Montpellier, France) adapted to a Cobas Mira Plus autoanalyzer (Roche Diagnostics, Madrid, Spain).
The categorical variables are expressed as percentages, and significant differences were identified using the chi-square test or Fisher's exact test, as appropriate. The quantitative variables, represented as the mean AE standard deviation (SD), were analyzed using Student's t-test. Spearman's correlation was used to identify linear relationships between the ascending aorta diameter and the parameters related to cholesterol metabolism. Stepwise linear regression models were used to identify independent predictors of the ascending aorta diameter, and stepwise logistic regression was used to identify independent predictors of AAD. Variables with a P value <0.10 in the univariate analysis were included in the multivariate analysis. P values <0.05 were considered significant. The statistical analysis was performed using SPSS software, Version 18.0 (IBM, Chicago, IL).
Results
The baseline clinical characteristics of the patients are shown in Table 1 . Most patients were men, and there was a high prevalence of valve dysfunction and aortic dilatation.
We observed significant linear correlations when comparing both the aortic root and ascending aorta diameters, with the levels of total cholesterol, LDL cholesterol and ApoB; these relationships were more evident after excluding those patients treated with statins (Table 2; Figure 1 ). Furthermore, the relationship between ascending aorta diameter with LDL cholesterol was slightly improved when only the younger half of the patient group (<50 years old) was considered (R = 0.53 and P value < 0.001). Using a linear regression model that included other factors related to the diameter of the ascending aorta, including age, valve morphology and the aortic transvalvular gradient, LDL and ApoB were identified as independent factors predictor of the aortic root diameter, although only ApoB predicted the diameter of the ascending aorta (Table 3) .
On the other hand, we observed that the BAV patients who were diagnosed with aortic dilatation had significantly higher levels of LDL cholesterol (2.9 AE 0.8 vs. 2.5 AE 0.9 mmol/l; P = 0.03) and ApoB (95 AE 21 vs. 82 AE 25 mg/dl; P = 0.01) compared to the non-dilated BAV patients (Figure 2 ). When we considered the BAV dilatation morphology, the levels of LDL and ApoB were similar between the ascending and the root phenotypes (2.9 AE 0.1 vs. 3.0 AE 0.2 mmol/l; P = 0.471 for LDL, and 94.85 AE 3 vs. 96.1 AE 6 mg/dl; P = 0.866 for ApoB). The small number of patients treated with statins limited an adequate analysis to evaluate its effect on the dilatation of the aorta. Using logistic regression, ApoB levels, adjusting for age, aortic stenosis and valve morphology, remained as an independent factor related to aortic dilatation ( = 0.022 mg/dl, P = 0.04 for the aortic root; = 0.051 mg/dl and P < 0.01 for the ascending aorta).
Discussion
In this study, we observed that in BAV patients, LDL and ApoB levels were associated with the diameter of the ascending aorta and AAD, independent of other related factors. Although the metabolism of cholesterol (specifically, the LDL cholesterol levels) has previously been related to abdominal aorta dilation, [11] [12] [13] the influence of cholesterol metabolism on ascending aorta dilatation in BAV patients had not been previously determined.
The pathobiology of aortic dilatation involves complex mechanisms. Thus, while extracellular matrix degeneration predominates in the ascending aorta, including the AAD in BAV, 17, 18 in the abdominal aorta, an inflammatory process linked to atheromatosis interplays with extracellular matrix degeneration. 19 Some common mechanisms, such as the role of matrix metalloproteinases (MMP) [20] [21] [22] and angiotensin [23] [24] [25] , have been implicated in both processes. Epidemiological studies have linked higher cholesterol levels with an increased risk of abdominal aorta dilatation. 10, [26] [27] [28] Recently, in an experimental mouse model of angiotensin-II abdominal aorta aneurysm, LDL emerged as a determinant factor for aneurysm size. 13 The oxidized form of LDL, oxLDL, has been recognized as an underlying mechanism related to the dysfunction and injury of the vascular endothelium. Thus, increased LDL levels within the arterial wall are an inflammation-triggering factor; they trigger a response characterized by the recruitment of macrophages and the release of inflammatory mediators, including the secretion of MMPs 29, 30 , which are endopeptidases that are crucial for extracellular matrix remodeling.
Furthermore, previous studies have demonstrated a link between the expression and activity of MMP-9 and LDL cholesterol levels. 31 Cholesterol is involved in endothelial dysfunction and this modulates the remodelling of vascular wall through processes such as inflammation and apoptosis. 32 Animal and human studies have suggested that statins limit abdominal aortic aneurysm formation or progression through molecular mechanisms that include a reduction in the expression of inflammatory biomarkers, such as interleukin-6 and MMPs, and mechanisms related to angiotensin-II. 33, 34 Thus, our data support the involvement of cholesterol metabolism in AAD in BAV patients. Further experimental and clinical studies are needed to explain the pathobiology of this association and to prospectively test the potential benefit of statins. The characteristics of aortic flow and aortic wall of BAV could influence the predisposition of BAV patients to the cholesterol effects. However, our results do not exclude about the possibility to also observe this effect in patients with tricuspid aortic valve. As consequence of the differences observed between the clinical characteristics and burden of cardiovascular risk factors between BAV and tricuspid aortic valve patients with AAD, more specific studies are required to explore this possibility. Our results demonstrated a close association between LDL and ApoB. This relationship is expected because ApoB is the main apolipoprotein present in LDL cholesterol [although it is also present in very low-density lipoprotein, intermediatedensity lipoprotein (IDL) and Lp (a)]. We have observed a similar relation of it on aortic root and ascending aorta. On the other hand, the associations between the LDL cholesterol and ascending aorta diameters were more evident in the younger half of the patients group. The higher prevalence of other factors related to aortic dilatation as hypertension 35 in older patients and the effect of aging in the degenerative process of the extracellular matrix 36 may contribute to this finding.
In conclusion, we have observed that cholesterol metabolism, particularly the ApoB and LDL cholesterol levels, is associated with the ascending aorta diameter and suggest that may contribute to dilatation in BAV patients. Our results invite to investigate the possible mechanisms that underlie this association.
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